MA38395B1 - Marqueurs associés à des inhibiteurs de la voie wnt - Google Patents

Marqueurs associés à des inhibiteurs de la voie wnt

Info

Publication number
MA38395B1
MA38395B1 MA38395A MA38395A MA38395B1 MA 38395 B1 MA38395 B1 MA 38395B1 MA 38395 A MA38395 A MA 38395A MA 38395 A MA38395 A MA 38395A MA 38395 B1 MA38395 B1 MA 38395B1
Authority
MA
Morocco
Prior art keywords
wnt pathway
inhibitor
inhibitors
markers associated
methods
Prior art date
Application number
MA38395A
Other languages
English (en)
Other versions
MA38395A1 (fr
Inventor
Jun Liu
Nicholas Ng
Jianwei Che
Jennifer Harris
Hsin-I Hsieh
Jie Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38395A1 publication Critical patent/MA38395A1/fr
Publication of MA38395B1 publication Critical patent/MA38395B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à des procédés de contrôle de l'expression génique différentielle de biomarqueurs servant à déterminer la sensibilité d'un patient à un inhibiteur de la voie wnt, des procédés de détermination de la sensibilité d'une cellule à un inhibiteur de la voie wnt par mesure de biomarqueurs, des procédés de recherche d'un inhibiteur de la voie wnt candidat, et un inhibiteur de la voie wnt destiné à être utilisé dans un carcinome malpighien de la tête et du cou.
MA38395A 2013-03-11 2014-03-10 Marqueurs associés à des inhibiteurs de la voie wnt MA38395B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776334P 2013-03-11 2013-03-11
PCT/IB2014/059585 WO2014141038A2 (fr) 2013-03-11 2014-03-10 Marqueurs associés à des inhibiteurs de la voie wnt

Publications (2)

Publication Number Publication Date
MA38395A1 MA38395A1 (fr) 2018-02-28
MA38395B1 true MA38395B1 (fr) 2018-09-28

Family

ID=50382514

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38395A MA38395B1 (fr) 2013-03-11 2014-03-10 Marqueurs associés à des inhibiteurs de la voie wnt

Country Status (26)

Country Link
US (1) US10422007B2 (fr)
EP (1) EP2972372B1 (fr)
JP (1) JP6445984B2 (fr)
KR (1) KR102194746B1 (fr)
CN (1) CN105190313B (fr)
AU (1) AU2014229424B2 (fr)
BR (1) BR112015019567A8 (fr)
CA (1) CA2903976C (fr)
CL (1) CL2015002572A1 (fr)
DK (1) DK2972372T3 (fr)
ES (1) ES2681618T3 (fr)
HK (1) HK1212771A1 (fr)
HU (1) HUE039776T2 (fr)
IL (1) IL240794A (fr)
MA (1) MA38395B1 (fr)
MX (1) MX2015012534A (fr)
PH (1) PH12015501778A1 (fr)
PL (1) PL2972372T3 (fr)
PT (1) PT2972372T (fr)
RU (2) RU2017141378A (fr)
SG (1) SG11201505873VA (fr)
SI (1) SI2972372T1 (fr)
TN (1) TN2015000325A1 (fr)
TW (1) TWI582239B (fr)
WO (1) WO2014141038A2 (fr)
ZA (1) ZA201505227B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015119552B4 (de) * 2015-10-23 2022-06-15 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige Zusammensetzung zur Behandlung von Tumor- und/oder Krebserkrankungen
CN105617359A (zh) * 2015-12-31 2016-06-01 中国科学院成都生物研究所 Wnt信号通路蛋白Frzb在制备抗肝癌药中的应用
WO2017167150A1 (fr) * 2016-03-31 2017-10-05 苏州云轩医药科技有限公司 Composé hétérocyclique 3-fluoropyridine et son application
CN106434968B (zh) * 2016-11-18 2019-10-22 北京致成生物医学科技有限公司 Ccdc168作为标记物在检测胰腺癌试剂中的应用
TW202016316A (zh) * 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
WO2020030708A1 (fr) * 2018-08-07 2020-02-13 Piqur Therapeutics Ag Traitement du carcinome à cellules squameuses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
ES2313756T3 (es) * 1997-10-29 2009-03-01 Genentech, Inc. Usos de polipeptido secretado wisp-1 inducido por wnt-1.
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
BRPI0410634A (pt) 2003-05-30 2006-06-13 Astrazeneca Uk Ltd processo
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
CA2586781A1 (fr) 2004-11-10 2006-05-18 Hubrecht Laboratorium Traitement d'un adenome et/ou d'un adenocarcinome intestinal par inhibition de l'activation de la voie notch
WO2006110585A2 (fr) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Genes lies au cancer (prlr)
WO2009074968A2 (fr) * 2007-12-12 2009-06-18 Ecole Polytechnique Federale De Lausanne (Epfl) Methode de prevision de l'efficacite d'un traitement anticancereux
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
JP2013506836A (ja) * 2009-10-02 2013-02-28 サイリーン ファーマシューティカルズ インコーポレーティッド プロテインキナーゼｃｋ２介在性疾患のｃｋ２阻害剤に対する感受性および反応を予測するバイオマーカー
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2552953B1 (fr) 2010-04-01 2017-05-17 OncoMed Pharmaceuticals, Inc. Agents de liaison aux récepteurs frizzled et leurs utilisations
EP2549399A1 (fr) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Evaluation d'activité de voie Wnt utilisant un modelage probabilistique d'expression de gène cible

Also Published As

Publication number Publication date
CA2903976A1 (fr) 2014-09-18
RU2663701C2 (ru) 2018-08-08
PH12015501778A1 (en) 2015-12-07
PT2972372T (pt) 2018-07-31
RU2015138688A (ru) 2017-04-17
EP2972372B1 (fr) 2018-04-25
KR102194746B1 (ko) 2020-12-24
CN105190313A (zh) 2015-12-23
RU2017141378A (ru) 2019-02-14
SG11201505873VA (en) 2015-09-29
TWI582239B (zh) 2017-05-11
KR20150127611A (ko) 2015-11-17
MA38395A1 (fr) 2018-02-28
TW201439328A (zh) 2014-10-16
IL240794A (en) 2017-09-28
CL2015002572A1 (es) 2016-03-28
SI2972372T1 (sl) 2018-09-28
MX2015012534A (es) 2016-01-12
BR112015019567A8 (pt) 2019-11-26
RU2017141378A3 (fr) 2020-12-15
WO2014141038A3 (fr) 2014-11-27
AU2014229424B2 (en) 2017-03-02
PL2972372T3 (pl) 2018-09-28
HK1212771A1 (zh) 2016-06-17
IL240794A0 (en) 2015-10-29
CA2903976C (fr) 2022-02-15
AU2014229424A1 (en) 2015-08-20
TN2015000325A1 (en) 2017-01-03
DK2972372T3 (en) 2018-07-30
JP2016513456A (ja) 2016-05-16
CN105190313B (zh) 2018-06-19
JP6445984B2 (ja) 2018-12-26
US10422007B2 (en) 2019-09-24
EP2972372A2 (fr) 2016-01-20
ES2681618T3 (es) 2018-09-14
US20160024587A1 (en) 2016-01-28
BR112015019567A2 (pt) 2017-07-18
WO2014141038A2 (fr) 2014-09-18
ZA201505227B (en) 2016-03-30
HUE039776T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
MA38395B1 (fr) Marqueurs associés à des inhibiteurs de la voie wnt
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
UY35385A (es) ?métodos y composiciones para el control de malezas?.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016017414A2 (pt) Uso de polímeros
TWD183792S (zh) 捲尺
CL2016002419A1 (es) Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata
AR102517A1 (es) Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso
EA201591931A1 (ru) Композиции оксабициклогептанов и оксабициклогептенов
BR112017007068A2 (pt) ?método para operar um medidor de fluxo, e, medidor de fluxo?
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
BR112017023473A2 (pt) método de detecção e quantificação de ácido nucleico e composições
AR105567A1 (es) Determinación del volumen de desgaste tubular utilizando factores de desgaste ajustables
AR088245A1 (es) Caracterizacion de la proteina y el gen cho-mif y uso de los mismos
IT201700038903A1 (it) Un interferometro birifrangente per misurare le proprieta’ di fotoluminescenza di campioni.
UA96896U (uk) Спосіб діагностики загострення хозл, поєднаного із остеоартрозом
AR110686A1 (es) Un procedimiento para identificar el sexo fetal
PL403360A1 (pl) Sposób i zestaw do wykrywania genetycznie uwarunkowanej predyspozycji do posiadania określonego koloru włosów
UA97451U (en) Method for predicting flow of pulmonary sarcoidosis
PL414457A1 (pl) Nowa linia komórkowa carcinoma mucoepidermale oraz jej zastosowanie do badań in vitro
LV15325A (lv) Lietotāja astroloģisko datu izmantošanas paņēmiens mērķinformācijas nodrošināšanai
TWD175568S (zh) 雪鏡(一)